Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patiromer to optimize RAAS blockade in chronic kidney disease with hyperkalemia
2020-001595-15Phase 4Completed
- Sponsor
- Henrik Birn
- Start
- Apr 2020
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4 trial of patiromer in chronic kidney disease (CKD), albuminuria and hyperkalemia (2 arms), sponsored by Henrik Birn. Primary endpoint: Change in albuminuria. Started Apr 2020; status: completed.
02
Drugs
patiromer
03
Conditions
chronic kidney disease (CKD)albuminuriahyperkalemia
Beyond the preview
Go deeper on 2020-001595-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001595-15.